Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Americas

Americas Pharmaceuticals & Healthcare Insight provides country-by-country analysis of the key trends impacting the prescription, OTC and generic drugs industries across the Americas. Americas Pharmaceuticals & Healthcare Insight includes competitive intelligence on the growth strategies of leading national and multinational companies, along with 5-year industry forecasts for each country. The service includes access to the very latest analysis, a searchable archive of articles and data and the ability to download PDFs of current and back issues.

›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.

›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.


Latest Stories

United States / Industry

BMI View: If successfully developed and marketed, Bristol-Myer Squibb (BMS)'s investigational combination immuno-oncology therapy will potentially be a leader in the market for skin cancer treatments, outperforming similar medicines from Merck & Co and Roche. However, although anticipation of positive trial results from the combination therapy is improving investor confidence,... 2013-05-20


Ecuador / Industry

BMI View: The steadily growing Ecuadorian pharmaceutical market will provide revenue-earning opportunities for Takeda. However, the limited market size and low per capita spending on... 2013-03-22


Industry

BMI View: Despite the undoubted clinical and commercial success of traditional chemotherapy, demand for new targeted cancer therapies is likely to remain high. This will provide continued... 2013-03-22


Industry Developments

United States

BMI View: If successfully developed and marketed, Bristol-Myer Squibb (BMS)'s investigational combination immuno-oncology therapy will potentially be a leader in the market for skin... 2013-05-20


Ecuador

BMI View: The steadily growing Ecuadorian pharmaceutical market will provide revenue-earning opportunities for Takeda. However, the limited market size and low per capita spending on... 2013-03-22


BMI View: Despite the undoubted clinical and commercial success of traditional chemotherapy, demand for new targeted cancer therapies is likely to remain high. This will provide continued... 2013-03-22


United States

BMI View: The outcome of the recent compulsory licence application to manufacture a generic version of Bristol-Myers Squibb (BMS)'s Sprycel (dasatinib) will likely favour the Indian... 2013-03-19